RMAM
NWBO

Raab & Moskowitz Asset Management’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Raab & Moskowitz Asset Management’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-431
Closed -$2K – 495
2014
Q4 		$2K Buy
+431
New +$2.21K ﹤0.01% 458

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raab & Moskowitz Asset Management's NWBO Position: Q1 2015 in Review

Raab & Moskowitz Asset Management sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2015, closing a stake of 431 shares — an estimated $2K sold.

Raab & Moskowitz Asset Management first reported a position in NWBO in Q4 2014 and held it in 1 quarter. The position peaked at $2K in Q4 2014. 75 funds tracked by Wall St. Rank hold NWBO as of Q1 2015.

  • Raab & Moskowitz Asset Management reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2015 after selling out during the quarter.
  • Raab & Moskowitz Asset Management sold 431 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2015, an estimated $2K.
  • Raab & Moskowitz Asset Management first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q4 2014 and held it in 1 quarter.
  • Raab & Moskowitz Asset Management's Northwest Biotherapeutics, Inc. Common stock position peaked at $2K in Q4 2014.
  • 75 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2015.

Based on Raab & Moskowitz Asset Management's 13F filing for Q1 2015, filed 12 May 2015.